Plain-English translation of NCT05435495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This trial is studying a radioactive treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to understand why some men respond well to this medication while others do not — specifically, whether it depends on how much radiation reaches the tumors or on how resistant the cancer cells are to radiation. By collecting tissue samples and special imaging scans, they hope to develop better ways to predict who will benefit most from this treatment.
Some men with advanced prostate cancer have tumors that stop responding to this radioactive treatment even though it works for others. Right now, doctors don't have a reliable way to predict which patients will benefit or to understand the biological reasons why resistance develops. This study aims to fill that gap so future treatment can be better tailored to individual patients.
You likely qualify if…
You likely don't qualify if…
You would have a tumor biopsy and blood draw before starting your treatment. Then, 24 hours after your first treatment dose and again 24 hours after your fourth dose, you would receive special imaging scans called SPECT/CT to see how the medication is working. If your cancer progresses during treatment, you may be asked to provide another tumor biopsy and blood sample. The entire study spans the length of your treatment course (at least four doses).
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Sponsor
University of California, San Francisco
Collaborators
National Cancer Institute (NCI), Prostate Cancer Foundation
Enrollment target
~125 participants
Started
October 2021
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maya Aslam
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.